Topology predicts long-term functional outcome in early psychosis.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
26
07
2019
accepted:
17
06
2020
revised:
05
06
2020
pubmed:
8
7
2020
medline:
1
2
2022
entrez:
8
7
2020
Statut:
ppublish
Résumé
Early intervention in psychosis is crucial to improving patient response to treatment and the functional deficits that critically affect their long-term quality of life. Stratification tools are needed to personalize functional deficit prevention strategies at an early stage. In the present study, we applied topological tools to analyze symptoms of early psychosis patients, and detected a clear stratification of the cohort into three groups. One of the groups had a significantly better psychosocial outcome than the others after a 3-year clinical follow-up. This group was characterized by a metabolic profile indicative of an activated antioxidant response, while that of the groups with poorer outcome was indicative of oxidative stress. We replicated in a second cohort the finding that the three distinct clinical profiles at baseline were associated with distinct outcomes at follow-up, thus validating the predictive value of this new stratification. This approach could assist in personalizing treatment strategies.
Identifiants
pubmed: 32632207
doi: 10.1038/s41380-020-0826-1
pii: 10.1038/s41380-020-0826-1
pmc: PMC8589664
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5335-5346Informations de copyright
© 2020. The Author(s).
Références
Hegelstad WTV, Larsen TK, Auestad B, Evensen J, Haahr U, Joa I, et al. Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. Am J Psychiatry. 2012;169:374–80.
pubmed: 22407080
Baumann PS, Crespi S, Marion-Veyron R, Solida A, Thonney J, Favrod J, et al. Treatment and early intervention in psychosis program (TIPP-Lausanne): implementation of an early intervention programme for psychosis in Switzerland. Early Inter Psychiatry. 2013;7:322–8.
Hastrup LH, Kronborg C, Bertelsen M, Jeppesen P, Jorgensen P, Petersen L, et al. Cost-effectiveness of early intervention in first-episode psychosis: economic evaluation of a randomised controlled trial (the OPUS study). Br J Psychiatry. 2013;202:35–41.
pubmed: 23174515
McGorry P, Johanessen JO, Lewis S, Birchwood M, Malla A, Nordentoft M, et al. Early intervention in psychosis: keeping faith with evidence-based health care: a commentary on: ‘Early intervention in psychotic disorders: faith before facts?’ by Bosanac et al. (). Psychol Med. 2010;40:399–404.
pubmed: 19775497
McGorry PD. Early intervention in psychosis: obvious, effective, overdue. J Nerv Ment Dis. 2015;203:310–8.
pubmed: 25919380
pmcid: 4414340
Nordentoft M. Specialised assertive intervention in early psychosis. Lancet Psychiatry. 2015;2:2–3.
pubmed: 26359592
Velthorst E, Fett A-KJ, Reichenberg A, Perlman G, van Os J, Bromet EJ, et al. The 20-year longitudinal trajectories of social functioning in individuals with psychotic disorders. Am J Psychiatry. 2017;174:1075–85.
pubmed: 27978770
Koutsouleris N, Kahn RS, Chekroud AM, Leucht S, Falkai P, Wobrock T, et al. Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach. Lancet Psychiatry. 2016;3:935–46.
pubmed: 27569526
Conus P, Cotton S, Schimmelmann BG, McGorry PD, Lambert M. Rates and predictors of 18-months remission in an epidemiological cohort of 661 patients with first-episode psychosis. Soc Psychiatry Psychiatr Epidemiol. 2017;52:1089–99.
pubmed: 28477070
Cotton SM, Lambert M, Schimmelmann BG, Filia K, Rayner V, Hides L, et al. Predictors of functional status at service entry and discharge among young people with first episode psychosis. Soc Psychiatry Psychiatr Epidemiol. 2017;52:575–85.
pubmed: 28233045
Conus P, Cotton SM, Francey SM, O’Donoghue B, Schimmelmann BG, McGorry PD, et al. Predictors of favourable outcome in young people with a first episode psychosis without antipsychotic medication. Schizophrenia Res. 2017;185:130–6.
Bergh S, Hjorthøj C, Sørensen HJ, Fagerlund B, Austin S, Secher RG, et al. Predictors and longitudinal course of cognitive functioning in schizophrenia spectrum disorders, 10 years after baseline: the OPUS study. Schizophrenia Res. 2016;175:57–63.
Rizvi AH, Camara PG, Kandror EK, Roberts TJ, Schieren I, Maniatis T, et al. Single-cell topological RNA-seq analysis reveals insights into cellular differentiation and development. Nat Biotechnol. 2017;35:551.
pubmed: 28459448
pmcid: 5569300
Nielson JL, Paquette J, Liu AW, Guandique CF, Tovar CA, Inoue T, et al. Topological data analysis for discovery in preclinical spinal cord injury and traumatic brain injury. Nat Commun. 2015;6:8581.
pubmed: 26466022
Bruno JL, Romano D, Mazaika P, Lightbody AA, Hazlett HC, Piven J, et al. Longitudinal identification of clinically distinct neurophenotypes in young children with fragile X syndrome. Proc Natl Acad Sci. 2017;114:10767–72.
pubmed: 28923933
pmcid: 5635864
Martinuzzi E, Barbosa S, Daoudlarian D, Bel Haj Ali W, Gilet C, Fillatre L, et al. Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. Transl Psychiatry. 2019;9:20.
pubmed: 30655509
pmcid: 6336802
Steullet P, Cabungcal JH, Monin A, Dwir D, O’Donnell P, Cuenod M, et al. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a “central hub” in schizophrenia pathophysiology? Schizophrenia Res. 2016;176:41–51.
Hardingham GE, Do KQ. Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nat Rev Neurosci. 2016;17:128–34.
Steullet P, Cabungcal JH, Coyle J, Didriksen M, Gill K, Grace AA, et al. Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia. Mol Psychiatry. 2017;22:936–43.
pubmed: 28322275
pmcid: 5491690
Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal. 2011;15:2011–35.
pubmed: 21126177
pmcid: 3159108
Cao B, Jin M, Brietzke E, McIntyre RS, Wang D, Rosenblat JD, et al. Serum metabolic profiling using small molecular water-soluble metabolites in individuals with schizophrenia: a longitudinal study using a pre–post-treatment design. Psychiatry Clin Neurosci. 2019;73:100–8.
pubmed: 30156046
Cao B, Wang D, Brietzke E, McIntyre RS, Pan Z, Cha D, et al. Characterizing amino-acid biosignatures amongst individuals with schizophrenia: a case–control study. Amino Acids. 2018;50:1013–23.
pubmed: 29796929
Oresic M, Tang J, Seppanen-Laakso T, Mattila I, Saarni SE, Saarni SI, et al. Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med. 2011;3:19.
pubmed: 21429189
pmcid: 3092104
He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, et al. Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012;2:e149.
pubmed: 22892715
pmcid: 3432190
Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, et al. Potential metabolite markers of schizophrenia. Mol Psychiatry. 2011;18:67.
pubmed: 22024767
pmcid: 3526727
Alvarez-Jimenez M, Gleeson JF, Henry LP, Harrigan SM, Harris MG, Amminger GP, et al. Prediction of a single psychotic episode: a 7.5-year, prospective study in first-episode psychosis. Schizophrenia Res. 2011;125:236–46.
Lin A, Wood SJ, Yung AR. Measuring psychosocial outcome is good. Curr Opin Psychiatry. 2013;26:138–43.
pubmed: 23318660
Golay P, Baumann PS, Jenni R, Do KQ, Conus P. Patients participating to neurobiological research in early psychosis: a selected subgroup? Schizophrenia Res. 2018;201:249–53.
Wallwork RS, Fortgang R, Hashimoto R, Weinberger DR, Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophrenia Res. 2012;137:246–50.
Tohen M, Hennen J, Zarate CM Jr., Baldessarini RJ, Strakowski SM, Stoll AL, et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry. 2000;157:220–8.
pubmed: 10671390
Andreasen NC, Carpenter WT Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441–9.
pubmed: 15741458
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. Washington (DC): American Psychiatric Association; 1994.
Singh G, Memoli F, Carlsson G. Topological Methods for the Analysis of High Dimensional Data Sets and 3D Object Recognition. Eurographics Association. 2007;91–100. https://doi.org/10.2312/SPBG/SPBG07/091-100 .
Gysin R, Kraftsik R, Boulat O, Bovet P, Conus P, Comte-Krieger E, et al. Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia. Antioxid Redox Signal. 2011;15:2003–10.
pubmed: 20673128
Conus P, Seidman LJ, Fournier M, Xin L, Cleusix M, Baumann PS, et al. N-acetylcysteine in a double-blind randomized placebo-controlled trial: toward biomarker-guided treatment in early psychosis. Schizophr Bull. 2018;44:317–27.
pubmed: 29462456
Alameda L, Fournier M, Khadimallah I, Griffa A, Cleusix M, Jenni R, et al. Redox dysregulation as a link between childhood trauma and psychopathological and neurocognitive profile in patients with early psychosis. Proc Natl Acad Sci. 2018;115:12495–500.
pubmed: 30455310
pmcid: 6298080
Xin L, Mekle R, Fournier M, Baumann PS, Ferrari C, Alameda L, et al. Genetic polymorphism associated prefrontal glutathione and its coupling with brain glutamate and peripheral redox status in early psychosis. Schizophr Bull. 2016;42:1185–96.
pubmed: 27069063
pmcid: 4988744
Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th ed. New York: W H Freeman; 2002. Section 23.3.
Irino Y, Toh R, Nagao M, Mori T, Honjo T, Shinohara M, et al. 2-Aminobutyric acid modulates glutathione homeostasis in the myocardium. Sci Rep. 2016;6:36749.
pubmed: 27827456
pmcid: 5101505
Soga T, Baran R, Suematsu M, Ueno Y, Ikeda S, Sakurakawa T, et al. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J Biol Chem. 2006;281:16768–76.
pubmed: 16608839
Ghosh S, Forney LA, Wanders D, Stone KP, Gettys TW. An integrative analysis of tissue-specific transcriptomic and metabolomic responses to short-term dietary methionine restriction in mice. PLoS ONE. 2017;12:e0177513.
pubmed: 28520765
pmcid: 5433721
Bonnot O, Klünemann HH, Sedel F, Tordjman S, Cohen D, Walterfang M. Diagnostic and treatment implications of psychosis secondary to treatable metabolic disorders in adults: a systematic review. Orphanet J Rare Dis. 2014;9:65.
pubmed: 24775716
pmcid: 4043981
Chen EYH, Tang JYM, Hui CLM, Chiu CPY, Lam MML, Law CW, et al. Three-year outcome of phase-specific early intervention for first-episode psychosis: a cohort study in Hong Kong. Early Intervention Psychiatry. 2011;5:315–23.
Golay P, Alameda L, Baumann P, Elowe J, Progin P, Polari A, et al. Duration of untreated psychosis: Impact of the definition of treatment onset on its predictive value over three years of treatment. J Psychiatr Res. 2016;77:15–21.
pubmed: 26950643
Niendam TA, Sardo A, Savill M, Patel P, Xing G, Loewy RL, et al. The rise of early psychosis care in California: an overview of community and university-based services. Psychiatr. Serv. 2019;70:480–7.
pubmed: 30890048
Rasmussen SA, Rosebush PI, Mazurek MF. Does early antipsychotic response predict long-term treatment outcome? Hum Psychopharmacol Clin Exp. 2017;32:e2633.
Alameda L, Golay P, Baumann P, Morandi S, Ferrari C, Conus P, et al. Assertive outreach for “difficult to engage” patients: a useful tool for a subgroup of patients in specialized early psychosis intervention programs. Psychiatry Res. 2016;239:212–9.
pubmed: 27016880
Conus P, Cotton S, Schimmelmann BG, McGorry PD, Lambert M. The First-Episode Psychosis Outcome Study: premorbid and baseline characteristics of an epidemiological cohort of 661 first-episode psychosis patients. Early Intervention Psychiatry. 2007;1:191–200.
Chang WC, Lau ESK, Chiu SS, Hui CLM, Chan SKW, Lee EHM, et al. Three-year clinical and functional outcome comparison between first-episode mania with psychotic features and first-episode schizophrenia. J Affect Disord. 2016;200:1–5.
pubmed: 27107261
Foussias G, Agid O, Fervaha G, Remington G. Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. Eur Neuropsychopharmacol. 2014;24:693–709.
pubmed: 24275699
Albert N, Bertelsen M, Thorup A, Petersen L, Jeppesen P, Le Quack P, et al. Predictors of recovery from psychosis: analyses of clinical and social factors associated with recovery among patients with first-episode psychosis after 5years. Schizophrenia Res. 2011;125:257–66.
Cacciotti-Saija C, Langdon R, Ward PB, Hickie IB, Guastella AJ. Clinical symptoms predict concurrent social and global functioning in an early psychosis sample. Early Intervention Psychiatry. 2018;12:177–84.
Üçok A, Serbest S, Kandemir PE. Remission after first-episode schizophrenia: results of a long-term follow-up. Psychiatry Res. 2011;189:33–7.
pubmed: 21196051
Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64:361–8.
pubmed: 18436195
Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, et al. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2013;36:185–92.
pubmed: 24201233